Vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors, and angiopoietin-2 inhibitors are examples of anti-angiogenic agents that are currently being used as potential strategies for angiogenesis inhibition therapy in RA [16,18,19,20]. This evidence concerns the gene VEGFA and rheumatoid arthritis.